

Pancreatic Lipase Inhibitors: Mechanistic Foundations, Structural Insights, and Emerging Medicinal Chemistry Strategies

Neil Birekumar Panchal^{1*} and Vipul Manusinh Vaghela²

¹Research scholar, Department of Pharmacy, Gujarat Technological University, Nr. Vishwakarma Government Engineering College, Gujarat, India

²Department of Pharmaceutical Chemistry, A. R. college of pharmacy and G. H. Patel institute of pharmacy, Gujarat, India.

<http://dx.doi.org/10.13005/bbra/3478>

(Received: 09 February 2026; accepted: 02 March 2026)

The main dietary triglyceride hydrolyzing catalyst, and a long time pharmacological parameter of decreased dietary caloric intake, is pancreatic lipase (PL). Recent progress in structural biology, high resolution crystallography and computational models has given a new understanding of the catalytic triad of PL and interfacial activation, lid dynamics and stabilization of colipase dependent. These mechanistic underpinnings have facilitated more rational search of the varied classes of inhibitors including covalent β -lactones to reversible natural products (flavonoids, aurones, chalcones) and contemporary synthetic scaffolds like thiazolidinedione, triazole, and multi-target hybrid chemotypes. The mechanism by which the inhibitors interact with the hydrophobic acyl-binding tunnel, oxyanion hole, and aromatic platform around Ser152 is now understood using quantitative structure-activity correlations, molecular docking, molecular dynamics simulations, and pharmacophore models. The new approaches to medicinal chemistry, such as allosteric inhibition of lid movement, partial inhibition to enhance the safety, the investigation of non-2-lactone electrophiles, and AI-assisted scaffold discovery provide avenues to effective, yet safer inhibitors. The enzymatic mechanism, structural biology, SAR trends, and computational methods have been incorporated in this review to present a single framework in designing next-generation pancreatic lipase inhibitors.

Keywords: Allosteric inhibition; Interfacial activation; Molecular docking; Molecular dynamics; Pancreatic lipase (PL); Pharmacophore modeling; QSAR; Scaffold hopping; Structure-based drug design.

Pancreatic lipase (PL) is the principal enzyme responsible for hydrolyzing dietary triglycerides into absorbable free fatty acids and monoglycerides.¹ Being the rate-limiting step of lipid assimilation, PL is a promising pharmacological target in reducing the caloric uptake and controlling obesity. However, the

theoretical simplicity of the approach to inhibition of fat-digestion has not been easily converted into the safe and effective pharmacotherapy. Orlistat, the sole clinically approved inhibitor is constrained by potency to tolerability trade-offs, gastro intolerance and insignificant weight loss in the long term.²

*Corresponding author E-mail: nbp9171@gmail.com



Clinical evidence reveals that orlistat achieves modest weight reduction of approximately 2.9 kg beyond placebo over 12 months, with only 37-54% of patients maintaining adherence due to gastrointestinal adverse events including steatorrhea, fecal urgency, and fat-soluble vitamin malabsorption.² The disconnect between biochemical potency (IC₅₀ ≈ 0.092 μM) and clinical outcomes highlights a fundamental challenge: complete lipase inhibition triggers compensatory mechanisms including increased ghrelin secretion, altered satiety signaling, and behavioral adaptation that diminish long-term efficacy.^{2,3} This potency-to-tolerability paradox necessitates a paradigm shift from maximal enzyme blockade toward controlled, partial inhibition strategies that preserve physiological lipid digestion while reducing caloric absorption.

Recent advances in structural biology, computational chemistry, natural-product exploration, and medicinal chemistry have revitalized interest in next-generation lipase modulators.³ A deeper understanding of interfacial activation, lid-domain dynamics, the colipase interaction surface, and substrate selectivity has uncovered new allosteric and partially inhibitory opportunities.^{1,4} In parallel, modern high-throughput screening, scaffold hopping, structure-guided design, and AI-assisted chemistry have expanded the chemical space⁵ of inhibitors far beyond α -lactones.⁶

This review synthesizes fundamental mechanistic insight into PL activation and catalysis, summarizes key natural and synthetic inhibitor classes, and highlights emerging medicinal-chemistry strategies — including allosteric modulation, multi-target hybrid scaffolds, and non- α -lactone electrophiles — that may overcome the limitations of classical inhibition.

Interfacial Activation

A defining feature of pancreatic lipase is interfacial activation, the dramatic increase in catalytic activity observed when the enzyme encounters a lipid–water interface. In aqueous solution, the active site is shielded by a mobile lid domain, which adopts a closed conformation. Upon interaction with lipid droplets, conformational rearrangements shift the lid into an open state, exposing the catalytic machinery and forming

a hydrophobic plateau optimized for substrate binding.⁷

It is activated by the action of colipase, which is a small cofactor that anchors PL to the mixed micelles in the presence of inhibitory bile salts. The interaction between the lid, colipase, and the lipid interface is critical to the effective turnover of the substrate as well as being a good target of interest when designing allosteric or partial inhibitors which seek to moderate activity rather than to block it.

Catalytic Triad and Mechanistic Chemistry

Like other serine hydrolases, PL employs a Ser–His–Asp catalytic triad (Ser152–His263–Asp176).⁸ Catalysis proceeds through:^{9,10}

1. Nucleophilic attack by Ser152 on the ester bond of the triglyceride, forming a tetrahedral intermediate stabilized by an oxyanion hole.
2. Acyl-enzyme formation after collapse of the intermediate and release of the first product.
3. Deacylation, where water (activated by His263) cleaves the acyl–enzyme intermediate to regenerate Ser152.

PL exhibits strong regiospecificity, preferentially hydrolyzing ester bonds at the sn-1 and sn-3 positions, yielding 2-monoglycerides as dominant products. This selectivity is governed by steric constraints within the active site and by subtle lid-domain positioning that guides substrate orientation.¹¹

Colipase Interaction and Structural Stabilization

In the intestinal lumen, bile salts form mixed micelles that can displace lipase from the lipid surface. Colipase overcomes this by binding tightly to PL, stabilizing the open lid conformation and anchoring the enzyme to micelles. The PL–colipase complex provides a broader hydrophobic surface for substrate entry. Structurally, co-crystallized complexes (e.g., PDB 1LPB and 1LPS) show how colipase contacts the C-terminal domain and helps maintain the catalytic configuration under physiological conditions.^{12,13}

Crystal Structures and Conformational States

Multiple high-resolution structures have revealed the conformational flexibility of PL:¹⁴

- 1LPB: PL–colipase complex, lid closed⁴
- 1LPS: PL–colipase with a phosphonate inhibitor, lid open¹⁵
- 1ETH: PL bound to a substrate analogue¹⁶
- 1N8S: Lipase-colipase-bile salt micelle complex¹

Together, these structures provide an invaluable foundation for rational inhibitor design, illuminating both the catalytic pocket and distal allosteric regions that may be exploited for partial inhibition

Classes of Pancreatic Lipase Inhibitors (Strengthened & More Concrete)

Pancreatic lipase inhibition has been explored across multiple chemical spaces, reflecting the enzyme's complex interplay of hydrophobic substrate binding, interfacial activation, and unique catalytic architecture.⁸

Effective inhibitors must reconcile two competing biochemical principles:³

1. High affinity for a deeply hydrophobic acyl-binding tunnel, and
2. Selective engagement with the catalytic machinery of Ser152–His263–Asp176 without inducing systemic exposure.

These dual constraints give rise to several distinct inhibitor classes, each shaped by specific structural, mechanistic, and physicochemical requirements.

̂-Lactones — Covalent, Mechanistically Precise, but Carrying a Potency–Tolerability Paradox

̂-Lactones represent the clearest chemical mimicry of the transition state for ester hydrolysis, explaining their unparalleled potency.¹⁷ Their strained four-membered ring positions the carbonyl exactly where the catalytic Ser152 nucleophile attacks, allowing rapid formation of a tetrahedral intermediate mimic that collapses into a stable covalent acyl-enzyme.¹⁸

Concrete mechanistic reasons for their potency

- The electrophilic ̂-lactone carbonyl is perfectly aligned with the oxyanion hole (Phe77, Leu153).¹⁷
- The long aliphatic side chain mimics a fatty acyl tail, optimally filling the lipophilic tunnel.
- Side-chain stereochemistry determines whether the carbonyl oxygen can “sit” in the oxyanion hole in a transition-state-like geometry.¹⁹

Potency range

Most ̂-lactones show inhibition in the low nanomolar to sub-micromolar region.¹⁹

Concrete limitation

Their irreversible covalent nature and hydrophobicity lead to:²

- Local gastrointestinal (GI) accumulation
- Broad suppression of fat digestion

- Tolerability issues (steatorrhea, oily spotting, dose-limiting symptoms)

This is why medicinal chemistry efforts increasingly target reversible or partially reversible alternatives.

Natural Product–Derived Inhibitors — Potent, Polyfunctional Chemotypes with Drug-Likeness Challenges

Natural products offer structural diversity not easily achievable synthetically. Their molecular frameworks often provide precisely positioned aromatic rings and hydrogen-bonding groups, enabling them to compete with orlistat in binding efficiency despite being reversible.

Flavonoids & Flavan-3-ols (Concrete SAR advantages)

Flavones and flavan-3-ols demonstrate inhibition by non-covalent stabilization of the lipase active site,²⁰ mainly by:

- δ – δ stacking with Phe77 and Tyr114²¹
- Hydrogen bonding to backbone NH groups forming the oxyanion hole.²⁰
- Hydrophobic insertion of phenyl rings into the acyl-binding tunnel.²¹

Potency range

- Flavones: 50–200 μ M²²
- Galloylated catechins: 0.05–2 μ M (exceptionally potent for natural products)²³

Why flavonoids matter

They illustrate that reversible, non-covalent scaffolds can be potent *if structural rigidity and hydrophobic patch distribution are optimized.*

Aurones — Undervalued but Mechanistically Rational Scaffolds

Aurones, with their benzofuranone core, align well with the lipase catalytic groove:

- Their carbonyl oxygen orients toward the oxyanion hole.²⁴
- The benzofuranone ring stacks against Phe77.^{4,24}
- Long alkoxy chains (C6–C10) mimic natural fatty acids and do not trigger covalent chemistry.^{4,25}

Potency

Often 1–10 μ M, with synthetic variants dipping <1 μ M.²⁵

Why important

Aurones bridge natural and synthetic space: they are rigid, planar, and lipophilic enough to bind well without needing an electrophilic warhead.

Chalcones — Tunable, Conjugated, and Lipase-Compatible

The α,β -unsaturated ketone moiety of chalcones provides:²⁶

- Anchor points for hydrogen bonding
- A conjugated δ system for aromatic stacking
- Highly modifiable 2,2',4,4'-OH pattern for binding orientation.²⁶
- Space for long-chain hydrophobic tail addition.²⁷

Potency

Ranges from low micromolar to $\sim 0.3 \mu\text{M}$ for optimized analogs.^{27,28}

Medicinal chemistry insight

Chalcones are ideal for rational scaffold extension into the acyl-binding channel.²⁸

Synthetic Scaffolds — Where Medicinal Chemistry Truly Begins

Thiazolidinedione (TZD) (Reversible Covalent Mimics without the Risks)

TZDs mimic the orientation of the catalytic serine's transition state but do so reversibly.²⁹ They engage the catalytic pocket by:

- Acting as hydrogen-bond acceptors.⁴
- Presenting large, polarizable aromatic “faces” to Phe77.^{4,30}
- Aligning substituents to occupy the hydrophobic channel.³⁰

Potency

Often 2–10 μM , with optimized derivatives approaching submicromolar.²⁹

Quinazolinone–Coumarin Hybrids — Dual-Action Precision

These scaffolds introduce:

- A quinazolinone core for hydrogen bonding near Ser152
- A coumarin chromophore for aromatic stacking.³¹
- Halogenated benzyl groups providing hydrophobic anchoring.³²

Unique advantage: simultaneous lipase + α -glucosidase inhibition — ideal for metabolic syndrome.³²

Triazoles — Small, Cheap, Stable, and Surprisingly Bioactive

1,2,3-Triazoles:

- Offer predictable synthetic access (CuAAC “click” chemistry).³³
- Provide heteroatom-rich surfaces for hydrogen bonding.³⁴
- Support bulky aromatic groups that fit the hydrophobic tunnel.³⁵

Potency

Low micromolar (1–5 μM) for optimized variants.³⁶

Unified Structure-Activity Principles Across Inhibitor Classes

Comparative analysis of all inhibitor classes reveals convergent SAR principles that define pancreatic lipase binding affinity:

Hydrophobic Tunnel Engagement: The acyl-binding channel accommodates linear chains of C10-C15 optimal length.^{4,17} β -Lactones exploit this with saturated fatty acid mimics, while aurones and chalcones achieve equivalent occupancy through extended alkoxy substituents (C6-C10).^{24,25,27} Chains shorter than C6 lose tunnel contacts; chains beyond C16 induce steric clashes with Ile209 and Val260.⁴

Aromatic Platform Interactions: Phe77 and Tyr114 form a δ -stacking platform essential for inhibitor orientation.²¹ Flavonoids position their B-ring against this surface, TZDs present thiazolidinedione aromatic faces, and triazoles dock heterocyclic cores. Compounds lacking planar aromatic systems show 10-50 fold potency loss regardless of other favorable features.^{37,38}

Catalytic Triad Recognition: Hydrogen bonding to Ser152 (directly or via water-mediated contacts) and His263 stabilizes the binding pose.³⁸ The oxyanion hole (Phe77, Leu153 backbone NHs) provides additional anchoring for carbonyl or hydroxyl acceptors. EGCG derivatives achieve sub-micromolar potency through simultaneous engagement of all three interaction nodes.^{24,39}

Conformational Compatibility: Rigid, planar scaffolds (aurones, chalcones, quinazolinones) maintain pre-organized conformations that minimize entropic penalties upon binding. Flexible inhibitors pay conformational costs that reduce effective binding free energy by 1-2 kcal/mol.

The integration of these four principles—rather than optimization of any single feature—distinguishes sub-micromolar inhibitors from weak binders across all chemical classes.

Table 1 provides a comprehensive comparison of representative inhibitors across all chemical classes, highlighting IC₅₀ values, mechanisms of action, and key structural determinants of potency.

Table 1. Representative Pancreatic Lipase Inhibitors

Class	Compound	IC ₅₀	Mechanism	Key Structural Features
β-Lactones	Lipstatin ¹⁷ Orlistat ¹⁸	0.14 μM 0.092 μM	Irreversible covalent Irreversible covalent	β-lactone, C13 unsaturated chain Saturated lipstatin derivative
Galloylated Catechins	EGCG-3,5-digallate ²³ Oolonghomobisflavan A ²³ EGCG ²³	0.098 μM 0.048 μM 0.349 μM	Reversible competitive Reversible competitive Reversible competitive	Di-galloylated flavan-3-ol Dimeric catechin Mono-galloylated
Flavones	42 -Amino baicalin Myricetin Quercetin Luteolin	<1.0 μM ~1.5 μM 1.5-128 μM 99 μM	Reversible competitive Reversible non-competitive Reversible non-competitive Reversible competitive	Modified pyrogallol core Hexahydroxy flavone Pentahydroxy flavone Tetrahydroxy flavone
Biflavones	Isoginkgetin ⁴⁰	2.9 μM	Reversible mixed	<i>Ginkgo</i> biflavone
Aurones	4,6-Dialkoxyaurone ²³	1.95 μM	Reversible	Long alkoxy chains (C6-C10)
Chalcones	Compound B13 ²⁷ Sanggenon D ⁴¹	0.33 μM 0.77 μM	Reversible mixed Reversible mixed	Two long carbon chains Diels-Alder adduct
TZD Derivatives	Arylidene-TZD (18a) ²⁹ Indole-TZD (7k) ³⁰	2.71 μM 7.30 μM	Reversible competitive Reversible competitive	2,5-Disubstituted arylidene Indole-3-carboxaldehyde hybrid
Quinazolinone-Coumarin	4-Bromo derivative ³²	2.85 μM	Reversible	Dual PL/á-glucosidase
Triazoles	p-Fluoro-benzyl ^{34,36}	1.1 μM	Reversible	Click chemistry product

Computational Approaches (Now More Concrete)

Computational tools are uniquely powerful for lipase because multiple high-resolution structures exist in both “open” and “closed” conformations. The enzyme’s deep, solvophobic pocket, its lid mobility, and the colipase interaction surface create a complex landscape ideally suited for *in silico* exploration.

Docking — What It Actually Reveals

Effective docking reveals:³⁷

- Whether the compound can position a hydrophobic chain parallel to the acyl-binding tunnel.⁴
- If its polar motifs can engage Ser152, His263, or oxyanion-hole NHs^{1,42}
- How well its aromatics align with Phe77 / Tyr114^{24,42}
- Whether bulky substituents clash with the lid domain.⁴

Docking consistently highlights a “triad interaction cluster” — the positioning of the ligand relative to Ser152, His263, and Phe77 predicts 60–80% of potency variance.

Molecular Dynamics (MD)— Capturing the Enzyme’s Real Behavior

MD reveals:⁴³

- Lid flexibility over 50–200 ns⁴⁴
- Stability of hydrogen bonds (Ser152/His263 occupancy %)^{4,44}

- Water molecules mediating key contacts⁴⁵
- Shape complementarity changes
- Whether bulky ligands distort the tunnel (undesirable)

For potent ligand–enzyme complexes:

- Root mean square deviation (RMSD): <3 Å³⁹
- Root mean square fluctuation (RMSF) (catalytic residues): <1.5 Å³⁹
- H-bond occupancy: >50%⁴⁵
- Hydrophobic tunnel remains undisturbed⁴

Quantitative Structure–Activity Relationship (QSAR) — What Actually Improves Potency

Across published QSAR models, three descriptor clusters consistently correlate with PL inhibition:

1. Hydrophobicity
 - Lipophilic interactions explain why C10–C15 chains outperform others.⁴⁶
2. Planarity & rigidity⁴⁷
 - Favorable for δ – δ stacking and entering the narrow tunnel.
3. H-bond acceptor count
 - Essential for catalytic triad engagement.^{38,46}

Revised rule-of-thumb:^{38,47}

LogP ~3–6 + planar core + one HBA near Ser152⁴² ! good starting point.




Fig. 1. Structural and mechanistic overview of human pancreatic lipase (hPL).

A. Interfacial activation via lid opening and colipase binding.

B. Catalytic machinery and modes of inhibitor binding.

Pharmacophore Models — The “Minimum Binding Requirements”

Consensus pharmacophore typically includes:

- 1 Hydrogen bond acceptor (HBA) near Ser152.^{1,42}
- Two hydrophobic sites along the tunnel^{1,4}
- One aromatic ring for stacking⁴²
- Optional HBD for oxyanion hole stabilization

Any scaffold lacking the hydrophobic pair almost always shows weak activity.^{4,48}

Artificial Intelligence (AI) & Fragment-Based Drug Design (FBDD) — Modern Tools for a Traditionally Overlooked Target

- Machine learning (ML) models rapidly predict lipase inhibitors with >80% classification accuracy.^{47,49}
- Generative deep-learning models can propose non- $\hat{\alpha}$ -lactone scaffolds optimized for potency + GI confinement.^{50,51}
- FBDD identifies small tunnel-binding fragments that can be linked or merged to produce potent, lipophilic inhibitors without covalent warheads.⁵²

AI offers a path to lipase inhibitors without the problems of orlistat, a previously unthinkable direction.

Table 2 summarizes validation metrics from key computational studies, demonstrating strong correlations between in silico predictions and experimental potency data, validating these methodologies for prospective inhibitor design.

Comparative analysis of irreversible versus reversible inhibition strategies reveals

distinct trade-offs between potency, tolerability, and therapeutic flexibility (Table 3). While $\hat{\alpha}$ -lactones achieve superior enzymatic inhibition, reversible scaffolds offer advantages in safety profiles and mechanistic versatility that may prove decisive for next-generation therapeutics.

Future Medicinal Chemistry Strategies: Allosteric and Partial Inhibition (“Smart Inhibition”)

Instead of knocking out lipase activity entirely, future inhibitors aim for controlled attenuation:

- 40–70% inhibition.⁵⁴
- Minimal GI side effects
- Preserved gastrointestinal physiology
- Improved adherence
- Reduced compensatory overeating

Targeting the lid hinge, colipase interface, or surface loops provides viable allosteric entry points.^{4,54,58,59}

Multi-Target Chemotypes — Metabolic Network Thinking

Obesity is not a single-pathway disease. Hybrid molecules that act on:^{32,57}

- PL + $\hat{\alpha}$ -glucosidase.³²
- PL + peroxisome proliferator-activated receptor gamma (PPAR γ).⁵⁷
- PL + AMP-activated protein kinase (AMPK)⁶⁰ can modulate both fat and carbohydrate absorption while influencing systemic metabolism.




Fig. 2. Representative pancreatic lipase inhibitor structures. (A) Orlistat, the only FDA-approved inhibitor ($IC_{50} = 0.092 \mu M$). (B) EGCG-digallate, the most potent natural product ($IC_{50} = 0.098 \mu M$).

Dual-modulators = lower doses, fewer side effects, greater metabolic impact.⁶¹

Beyond β -Lactones — Safe Covalent and Non-Covalent Alternatives

Medicinal chemists are now exploring:

- Boronic acids (reversible covalent, tunable)^{62,63}
- Phenyl carbamates (stable, non-strained electrophiles)^{64,65}
- Soft electrophiles activated only near Ser152.⁶⁶

These promise potency without the toxicity of classic β -lactones.^{62,64}

Bridging the Translational Gap: Why Potent In Vitro Inhibitors Fail Clinically

Despite numerous inhibitors demonstrating sub-micromolar potency in enzymatic assays, only orlistat has achieved clinical approval, revealing critical translational barriers.³ Potent natural products like galloylated catechins (IC₅₀ € 0.048 iM) undergo extensive degradation in gastric acid, rapid enterocyte metabolism, and oxidative instability under intestinal conditions, dramatically

reducing effective concentrations at the lipid-water interface.^{23,56} Additionally, complete lipase inhibition triggers compensatory physiological responses—pancreatic enzyme hypersecretion, altered bile acid synthesis, and microbiome-mediated fat metabolism—explaining why 95% enzymatic inhibition translates to only 30% reduction in fat absorption clinically.² Overcoming these barriers requires integrated preclinical models incorporating simulated intestinal conditions and mechanistic biomarkers that predict clinical fat malabsorption beyond simple IC₅₀ € values.

Targeting the Lipophilic Tunnel — The Real Key to Potency

New scaffolds explicitly aim to:

- Extend into the hydrophobic tunnel.¹
- Position aromatic or aliphatic substituents to fill “hot spots”.⁴
- Exploit tunnel residues (Ile209, Leu213, Val260, Phe215).⁶⁷

Table 2. Computational Validation Metrics

Study	Method	Key Result	Correlation
Indole-TZD series ³⁰	AutoDock + in vitro	4 H-bonds with Ser152/His263	r = 0.91 (p<0.05)
Arylidene-TZD 18a ²⁹	Docking + 200ns MD	RMSD 2.8±0.4 Å, 3.2 H-bonds	$\Delta G = -32.5$ kcal/mol
Pyrazolyl-TZD 11e ⁵³	100ns MD simulation	Stable RMSD ~3 Å, Rg ~20.5 Å	Maintained integrity
Aurone derivatives ²⁴	Docking (82 compounds)	62/82 engaged catalytic triad	Tunnel occupancy key
Chalcone series ²⁷	Docking validation	Carbonyl H-bonds to Ser152/His263	R ² = 0.986
Flavonoid QSAR ⁴⁷	Multi-descriptor model	LogP, OH count, planarity	R ² = 0.82, Q ² = 0.75

Table 3. β -Lactone vs. Reversible Inhibitors – Comparative Profile

Parameter	β -Lactones	Reversible Inhibitors
Potency (IC ₅₀) ^{18,23,29}	0.092 iM	0.048-2.85 μ M
Mechanism ^{17,29}	Irreversible covalent	Reversible competitive/mixed
GI Tolerability ^{2,54}	Poor (steatorrhea 15-30%)	Improved (partial inhibition)
Systemic Exposure ^{55,56}	Minimal (<1%)	Variable (0.5-15%)
Chemical Stability ^{3,17,23,29}	High	Moderate
Selectivity ^{3,54}	Moderate	Higher (structure-dependent)
Allosteric Potential ⁵⁴	None	Possible
Multi-Target Capability ^{32,57}	Limited	High (hybrid scaffolds)
Clinical Stage ^{2,3}	Approved (1999)	Preclinical to Phase I

This is the feature α -lactones exploit — medicinal chemists can mimic it without irreversible chemistry.³

Designing GI-Localized Drugs

Best-in-class PL inhibitors will be:

- Highly lipophilic (LogP > 5)⁵⁵
- High molecular weight⁵⁵
- Poorly permeable^{55,56}
- Designed for local GI action⁵⁶
- Cleared almost exclusively in feces^{56,68,69}

This pharmacokinetic design is a feature, not a flaw — the exact opposite of classical drug design.

DISCUSSION

This comprehensive review synthesizes mechanistic, structural, and medicinal chemistry perspectives on pancreatic lipase inhibition, revealing both the molecular basis for current therapeutic limitations and the strategic pathways toward improved inhibitor design.

From Mechanism to Medicinal Chemistry: Integrating Biological Insights

The interfacial activation mechanism of pancreatic lipase—unique among digestive enzymes—presents both opportunities and challenges for inhibitor development.^{1,7} Unlike soluble enzymes where active-site geometry alone dictates binding, lipase requires inhibitors to function at lipid-water interfaces, engage dynamically with the lid domain, and compete with physiological substrates organized in mixed micelles. This explains why classical structure-activity relationship predictions often fail: compounds optimized for aqueous binding may not maintain potency under interfacial conditions.⁸

The catalytic triad (Ser152-His263-Asp176) and oxyanion hole provide well-defined molecular targets,^{8,9} yet α -lactone inhibitors—despite near-perfect transition-state mimicry^{17,18} suffer from irreversible chemistry that triggers compensatory physiological responses.² This potency-tolerability paradox underscores a critical lesson: maximal enzyme inhibition does not translate to optimal therapeutic outcomes. The future lies in partial, tunable inhibition (40-70% activity reduction)⁵⁴ that preserves basal lipid digestion while reducing caloric absorption.

Reversible Inhibitors as Safer Alternatives: Balancing Potency and Physiological Compatibility

Natural products, particularly galloylated catechins (IC₅₀ = 0.048 μ M) and optimized chalcones (IC₅₀ = 0.33 μ M),²⁷ demonstrate that reversible, non-covalent scaffolds can achieve potencies rivaling orlistat when designed for optimal hydrophobic tunnel occupancy and aromatic platform engagement.^{24,25} However, their clinical translation is hindered by metabolic instability, pH-dependent degradation, and poor formulation characteristics.^{23,56}

Synthetic scaffolds — thiazolidinediones,^{29,30} triazoles,³⁴⁻³⁶ quinazolinone-coumarin hybrids³² address these limitations through enhanced chemical stability and tunable pharmacokinetic properties. The quinazolinone-coumarin dual inhibitors represent a particularly promising strategy: simultaneous modulation of pancreatic lipase and α -glucosidase addresses both fat and carbohydrate absorption, potentially offering superior metabolic control with lower individual enzyme inhibition requirements.

Computational Tools: From Predictive Limitations to Strategic Utility

Molecular docking and dynamics simulations have proven invaluable for understanding binding modes and identifying key interaction hotspots (Ser152, His263, Phe77, Tyr114).^{37,42,70} However, their predictive accuracy for interfacial enzymes remains constrained by the inability to model lipid-water boundaries, bile salt effects, and colipase-mediated conformational changes. Computational tools should thus be viewed as hypothesis-generating and mechanistic-interrogation instruments rather than definitive predictors of in vivo efficacy.

QSAR models consistently identify lipophilicity (LogP 3-6), planarity, and hydrogen-bond acceptor capacity as dominant determinants of potency,^{46,47} but this risks reinforcing lipophilic bias that contributes to poor bioavailability and formulation challenges. Machine-learning and AI-driven scaffold generation⁵⁰⁻⁵² offer opportunities to escape this local chemical space, potentially identifying novel non- α -lactone frameworks optimized for both potency and drug-like properties.

Translational Barriers: Why In Vitro Potency Fails Clinically

The persistent disconnect between enzymatic potency and clinical efficacy reflects fundamental misalignments between experimental models and physiological reality.^{3,56} Simplified assays using p-nitrophenyl substrates bypass interfacial activation requirements, while in vivo fat digestion involves bile salt competition, colipase stabilization, and complex micellar organization.^{1,8} Furthermore, complete lipase inhibition triggers adaptive responses—pancreatic enzyme hypersecretion, altered bile acid synthesis, microbiome-mediated compensatory pathways—that diminish therapeutic impact despite sustained enzymatic blockade.²

Successful next-generation inhibitors must be designed with these physiological constraints in mind: GI-localized pharmacokinetics (high MW, extreme lipophilicity, poor permeability^{55,56}) to minimize systemic exposure; partial inhibition profiles to avoid triggering compensatory mechanisms; and multi-target activity to address metabolic dysfunction comprehensively rather than through single-enzyme modulation.

Strategic Priorities for Future Inhibitor Development

Four strategic directions emerge from this integrated analysis:

1. Allosteric and partial inhibition: Targeting the lid-colipase interface or surface loops^{54,58,71} to achieve controllable, tunable activity reduction without complete active-site blockade.
2. Multi-target hybrid molecules: Dual PL/α-glucosidase³² or PL/PPARα⁵⁷ inhibitors that address multiple metabolic pathways simultaneously, potentially reducing required doses and side-effect burden.
3. Non-β-lactone electrophiles: Boronic acids, carbamates, and sulfonyl fluorides^{62–66} offer reversible or slowly-reversible covalent mechanisms with reduced toxicity profiles compared to classical β-lactones.
4. GI-restricted pharmacokinetics: Deliberate design for intestinal localization^{55,56} through high molecular weight, extreme lipophilicity, and poor permeability—converting traditional “drug-likeness” liabilities into therapeutic assets.

The ultimate goal is not to replicate orlistat’s potency but to transcend its limitations:

achieving meaningful fat malabsorption with improved tolerability, adherence, and long-term sustainability. This requires embracing partial inhibition, allosteric modulation, and multi-target strategies that align molecular design with physiological reality.

CONCLUSION

Pancreatic lipase represents a structurally well-characterized hydrolytic enzyme whose inhibition offers rational obesity management through reduced dietary fat absorption. However, clinical success has been limited by orlistat’s potency-tolerability paradox: irreversible covalent inhibition triggers gastrointestinal side effects and compensatory physiological responses that diminish long-term efficacy.

This review demonstrates that future progress lies not in replicating orlistat’s mechanism but in transcending it through innovative medicinal chemistry. Reversible natural products—galloylated catechins, auronones, and chalcones—achieve sub-micromolar potencies when optimized for hydrophobic tunnel engagement and catalytic triad recognition. Synthetic scaffolds including thiazolidinediones, triazoles, and quinazolinone-coumarin hybrids extend this principle through enhanced stability, tunable pharmacokinetics, and multi-target capabilities.

Computational approaches combining molecular dynamics, QSAR modeling, and AI-driven scaffold generation provide mechanistic insights that accelerate rational inhibitor development, though interfacial enzyme behavior remains incompletely modeled.

Four strategic priorities define next-generation development: allosteric and partial inhibition targeting the lid-colipase axis; multi-target hybrids addressing both lipid and carbohydrate metabolism; non-β-lactone electrophiles offering safer covalent mechanisms; and GI-restricted pharmacokinetics through deliberate high molecular weight design.

Success requires embracing partial rather than maximal inhibition, allosteric rather than purely active-site targeting, and multi-target rather than single-enzyme modulation. By aligning molecular design with pancreatic lipase’s unique interfacial activation mechanism, next-generation

inhibitors can achieve meaningful clinical impact while avoiding orlistat's tolerability limitations

have read and approved the final manuscript for publication.

ACKNOWLEDGEMENT

The authors gratefully acknowledge the Almighty for guidance and strength, their families for unwavering support and, Gujarat Technological University, Ahmedabad, for providing the necessary institutional support and facilities that enabled the successful completion of this work.

AI Disclosure

Artificial intelligence tools (ChatGPT, GPT-5, OpenAI, USA) were used only for language refinement and grammar correction. All scientific content and interpretations are solely those of the authors.

Funding Sources

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of interest

The authors do not have any conflict of interest.

Data Availability Statement

This statement does not apply to this article.

Ethics Statement

This research did not involve human participants, animal subjects, or any material that requires ethical approval.

Informed Consent Statement

This study did not involve human participants, and therefore, informed consent was not required.

Clinical Trial Registration

This research does not involve any clinical trials.

Permission to reproduce material from other sources

Not Applicable

Author contributions

Neil Bienkumar Panchal: Conceptualization, Literature review, Data curation, Writing – Original draft, Visualization, Validation; Vipul Manusinh Vaghela: Supervision, Writing – Review & editing, Project administration, Final approval. All authors have read and approved the final manuscript for publication. All authors

REFERENCES

1. Van Tilbeurgh H, Egloff MP, Martinez C, Rugani N, Verger R, Cambillau C. Interfacial activation of the lipase–procolipase complex by mixed micelles revealed by X-ray crystallography. *Nat* 1993 3626423. 1993;362(6423):814-820. doi:10.1038/362814a0
2. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhaelidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. *Drug Saf.* 2008;31(1):53-65. doi:10.2165/00002018-200831010-00005
3. Lunagariya NA, Patel NK, Jagtap SC, Bhutani KK. Inhibitors of pancreatic lipase: state of the art and clinical perspectives. *EXCLI J.* 2014;13:897. Accessed November 18, 2025. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4464291/>
4. Egloff MP, Marguet F, Buono G, Verger R, Cambillau C, van Tilbeurgh H. The 2.46 Å resolution structure of the pancreatic lipase–colipase complex inhibited by a C11 alkyl phosphonate. *Biochemistry.* 1995;34(9):2751-2762. doi:10.1021/BI00009A003
5. Cerchia C, Lavecchia A. New avenues in artificial-intelligence-assisted drug discovery. *Drug Discov Today.* 2023;28(4):103516. doi:10.1016/J.DRUDIS.2023.103516
6. Tong X, Liu X, Tan X, et al. Generative Models for De Novo Drug Design. *J Med Chem.* 2021;64(19):14011-14027. doi:10.1021/ACS.JMEDCHEM.1C00927
7. Verger R. 'Interfacial activation' of lipases: facts and artifacts. *Trends Biotechnol.* 1997;15(1):32-38. doi:10.1016/S0167-7799(96)10064-0
8. Van Tilbeurgh H, Sarda L, Verger R, Cambillau C. Structure of the pancreatic lipase–procolipase complex. *Nat* 1992 3596391. 1992;359(6391):159-162. doi:10.1038/359159a0
9. Chapus C, Sémériva M. Mechanism of pancreatic lipase action. 2. Catalytic properties of modified lipases. *Biochemistry.* 1976;15(23):4988-4991. doi:10.1021/BI00668A007
10. Honeder SE, Tomin T, Schinagl M, et al. Research Advances Through Activity-Based Lipid Hydrolase Profiling. *Isr J Chem.* 2023;63(3-4):e202200078. doi:10.1002/IJCH.202200078;CSUBTYPE:STRING:SPECIAL;PAGE:STRING:ARTICLE/CHAPTER
11. Reis P, Miller R, Leser M, Watzke H. Lipase-

- catalyzed Reactions at Interfaces of Two-phase Systems and Microemulsions. *Appl Biochem Biotechnol.* 2008;158(3):706. doi:10.1007/S12010-008-8354-5
12. Van Tilbeurgh H, Bezzine S, Cambillau C, Verger R, Carrière F. Colipase: Structure and interaction with pancreatic lipase. *Biochim Biophys Acta - Mol Cell Biol Lipids.* 1999;1441(2-3):173-184. doi:10.1016/S1388-1981(99)00149-3
 13. Yang Y, Lowe ME. The open lid mediates pancreatic lipase function. *J Lipid Res.* 2000;41(1):48-57. doi:10.1016/s0022-2275(20)32073-3
 14. Winkler FK, D'Arcy A, Hunziker W. Structure of human pancreatic lipase. *Nat 1990 3436260.* 1990;343(6260):771-774. doi:10.1038/343771a0
 15. Lim SY, Steiner JM, Cridge H. Lipases: it's not just pancreatic lipase! *Am J Vet Res.* 2022;83(8). doi:10.2460/AJVR.22.03.0048
 16. Hermoso J, Pignol D, Kerfelec B, Crenon I, Chapus C, Fontecilla-Camps JC. Lipase Activation by Nonionic Detergents: THE CRYSTAL STRUCTURE OF THE PORCINE LIPASE-COLIPASE-TETRAETHYLENE GLYCOL MONOOCTYLETHER COMPLEX. *J Biol Chem.* 1996;271(30):18007-18016. doi:10.1074/JBC.271.30.18007
 17. Hochuli E, Kupfer E, Maurer R, Meister W, Mercadal Y, Schmidt K. Lipstatin, an inhibitor of pancreatic lipase, produced by *Streptomyces toxytricini*. II. Chemistry and structure elucidation. *J Antibiot (Tokyo).* 1987;40(8):1086-1091. doi:10.7164/ANTIBIOTICS.40.1086
 18. Hadvary P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. *Biochem J.* 1988;256(2):357-361. doi:10.1042/BJ2560357
 19. Camara K, Kamat SS, Lasota CC, Cravatt BF, Howell AR. Combining cross-metathesis and activity-based protein profiling: New α -lactone motifs for targeting serine hydrolases. *Bioorg Med Chem Lett.* 2015;25(2):317-321. doi:10.1016/J.BMCL.2014.11.038
 20. Wu X, He W, Yao L, et al. Characterization of Binding Interactions of (")-Epigallocatechin-3-gallate from Green Tea and Lipase. *J Agric Food Chem.* 2013;61(37):8829-8835. doi:10.1021/JF401779Z
 21. Park JY, Kim CS, Park KM, Chang PS. Inhibitory characteristics of flavonol-3-O-glycosides from *Polygonum aviculare* L. (common knotgrass) against porcine pancreatic lipase. *Sci Reports 2019 91.* 2019;9(1):18080-. doi:10.1038/s41598-019-54546-8
 22. Lee EM, Lee SS, Chung BY, et al. Pancreatic Lipase Inhibition by C-Glycosidic Flavones Isolated from *Eremochloa ophiuroides*. *Mol 2010, Vol 15, Pages 8251-8259.* 2010;15(11):8251-8259. doi:10.3390/MOLECULES15118251
 23. Nakai M, Fukui Y, Asami S, et al. Inhibitory effects of oolong tea polyphenols on pancreatic lipase in vitro. *J Agric Food Chem.* 2005;53(11):4593-4598. doi:10.1021/jf047814+
 24. Nguyen PTV, Huynh HA, van Truong D, Tran TD, Vo CVT. Exploring Aurone Derivatives as Potential Human Pancreatic Lipase Inhibitors through Molecular Docking and Molecular Dynamics Simulations. *Molecules.* 2020;25(20). doi:10.3390/MOLECULES25204657
 25. Thi Vo C Van, Thanh Nguyen T, Ngoc Dang T, et al. Design, synthesis, biological evaluation and molecular docking of alkoxyaurones as potent pancreatic lipase inhibitors. *Bioorg Med Chem Lett.* 2024;98:129574. doi:10.1016/J.BMCL.2023.129574
 26. Tam DNH, Mostafa EM, Tu VL, et al. Efficacy of chalcone and xanthine derivatives on lipase inhibition: A systematic review. *Chem Biol Drug Des.* 2020;95(2):205-214. doi:10.1111/CBDD.13626
 27. Huo PC, Hu Q, Shu S, et al. Design, synthesis and biological evaluation of novel chalcone-like compounds as potent and reversible pancreatic lipase inhibitors. *Bioorg Med Chem.* 2021;29:115853. doi:10.1016/J.BMC.2020.115853
 28. Jeong JY, Jo YH, Kim SB, et al. Pancreatic lipase inhibitory constituents from *Morus alba* leaves and optimization for extraction conditions. *Bioorganic Med Chem Lett.* 2015;25(11):2269-2274. doi:10.1016/j.bmcl.2015.04.045
 29. Dhiman P, Yadav N, Auti PS, et al. Discovery of thiazolidinedione-based pancreatic lipase inhibitors as anti-obesity agents: synthesis, in silico studies and pharmacological investigations. *J Biomol Struct Dyn.* 2025;43(12):5756-5778. doi:10.1080/07391102.2024.2310799
 30. George G, Auti PS, Paul AT. Design, synthesis, in silico molecular modelling studies and biological evaluation of novel indole-thiazolidinedione hybrid analogues as potential pancreatic lipase inhibitors. *New J Chem.* 2021;45(3):1381-1394. doi:10.1039/D0NJ05649A
 31. Ibrar A, Shehzadi SA, Saeed F, Khan I. Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery. *Bioorg Med Chem.* 2018;26(13):3731-3762. doi:10.1016/J.BMC.2018.05.042
 32. Mentepe E, Karaali N, Akyüz G, Yılmaz F, Ülker S, Kahveci B. Synthesis and Evaluation of α -Glucosidase and Pancreatic Lipase Inhibition

- by Quinazolinone-Coumarin Hybrids. *Chem Heterocycl Compd* 2017 5212. 2017;52(12):1017-1024. doi:10.1007/S10593-017-2002-3
33. Thirumurugan P, Matosiuk D, Jozwiak K. Click chemistry for drug development and diverse chemical-biology applications. *Chem Rev.* 2013;113(7):4905-4979. doi:10.1021/CR200409F
34. Ozdemir Y, Bekircan O, Balta^o N, Mente^oe E. Synthesis and pancreatic lipase inhibitory activities of some 1,2,4 triazol5(3) one derivatives. *J Heterocycl Chem.* 2020;57(12):4239-4253. doi:10.1002/JHET.4130
35. Kahveci B, Yılmaz F, Mentepe E, Ülker S. Design, Synthesis, and Biological Evaluation of Coumarin-Triazole Hybrid Molecules as Potential Antitumor and Pancreatic Lipase Agents. *Arch Pharm (Weinheim).* 2017;350(8). doi:10.1002/ARDP.201600369
36. Jalaja R, Leela SG, Valmiki PK, et al. Discovery of Natural Product Derived Labdane Appended Triazoles as Potent Pancreatic Lipase Inhibitors. *ACS Med Chem Lett.* 2018;9(7):662-666. doi:10.1021/ACSMEDCHEMLET.8B00109
37. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. *Nat Rev Drug Discov.* 2004;3(11):935-949. doi:10.1038/NRD1549
38. Allal H, Nemdili H, Zerizer MA, Zouchoune B. Molecular structures, chemical descriptors, and pancreatic lipase (1LPB) inhibition by natural products: a DFT investigation and molecular docking prediction. *Struct Chem* 2023 351. 2023;35(1):223-239. doi:10.1007/S11224-023-02176-2
39. Nirmale D, S. S. Insight into the interaction of human pancreatic lipase with potential anti-obesity drug, Cetilistat, using a molecular docking and molecular dynamics simulation. *TMR Pharmacol Res.* 2022;2(3):11. doi:10.53388/pr202202011
40. Liu PK, Weng ZM, Ge GB, et al. Biflavones from Ginkgo biloba as novel pancreatic lipase inhibitors: Inhibition potentials and mechanism. *Int J Biol Macromol.* 2018;118(Pt B):2216-2223. doi:10.1016/j.ijbiomac.2018.07.085
41. Hou XD, Ge GB, Weng ZM, et al. Natural constituents from Cortex Mori Radicis as new pancreatic lipase inhibitors. *Bioorg Chem.* 2018;80:577-584. doi:10.1016/j.bioorg.2018.07.011
42. Veeramachaneni GK, Raj KK, Chalasani LM, Bondili JS, Talluri VR. High-throughput virtual screening with e-pharmacophore and molecular simulations study in the designing of pancreatic lipase inhibitors. *Drug Des Devel Ther.* 2015;9:4397-4412. doi:10.2147/DDDT.S84052
43. Hollingsworth SA, Dror RO. Molecular Dynamics Simulation for All. *Neuron.* 2018;99(6):1129-1143. doi:10.1016/j.neuron.2018.08.011
44. Salo-Ahen OMH, Alanko I, Bhadane R, et al. Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development. *Process* 2021, Vol 9, Page 71. 2020;9(1):71. doi:10.3390/PR9010071
45. Rudling A, Orro A, Carlsson J. Prediction of Ordered Water Molecules in Protein Binding Sites from Molecular Dynamics Simulations: The Impact of Ligand Binding on Hydration Networks. *J Chem Inf Model.* 2018;58(2):350-361. doi:10.1021/ACS.JCIM.7B00520
46. Li YF, Chang YQ, Deng J, et al. Prediction and evaluation of the lipase inhibitory activities of tea polyphenols with 3D-QSAR models. *Sci Reports* 2016 61. 2016;6(1):34387-. doi:10.1038/srep34387
47. Yuan Y, Pan F, Zhu Z, et al. Construction of a QSAR Model Based on Flavonoids and Screening of Natural Pancreatic Lipase Inhibitors. *Nutrients.* 2023;15(15). doi:10.3390/NU15153489
48. Zhai Y, Wang K, Yu Z, Zhou S, Fan J. Pancreatic lipase inhibitors: Virtual screening and mechanistic analysis. *Int J Biol Macromol.* 2025;310:143128. doi:10.1016/J.IJBIOMAC.2025.143128
49. Liu Y, Pan F, Wang O, et al. QSAR model of pancreatic lipase inhibition by phenolic acids and their derivatives based on machine learning and multi-descriptor strategy. *J Agric Food Res.* 2023;14:100783. doi:10.1016/J.JAFR.2023.100783
50. Jiang Y, Zhang G, You J, et al. PocketFlow is a data-and-knowledge-driven structure-based molecular generative model. *Nat Mach Intell* 2024 63. 2024;6(3):326-337. doi:10.1038/s42256-024-00808-8
51. Sun H, Li J, Zhang Y, et al. Hot-Spot-Guided Generative Deep Learning for Drug-Like PPI Inhibitor Design. *Interdiscip Sci.* Published online 2025. doi:10.1007/S12539-025-00756-W
52. Keseru GM, Erlanson DA, Ferenczy GG, Hann MM, Murray CW, Pickett SD. Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia. *J Med Chem.* 2016;59(18):8189-8206. doi:10.1021/ACS.JMEDCHEM.6B00197
53. S.N.C. S, Bhurta D, Kantiwal D, George G, Monga V, Paul AT. Design, synthesis, biological evaluation and molecular modelling

- studies of novel diaryl substituted pyrazolyl thiazolidinediones as potent pancreatic lipase inhibitors. *Bioorg Med Chem Lett*. 2017;27(16):3749-3754. doi:10.1016/J.BMCL.2017.06.069
54. Moreno-Córdova EN, Arvizu-Flores AA, Valenzuela-Soto EM, et al. Gallotannins are uncompetitive inhibitors of pancreatic lipase activity. *Biophys Chem*. 2020;264. doi:10.1016/j.bpc.2020.106409
55. Dorel R, Wong AR, Crawford JJ. Trust Your Gut: Strategies and Tactics for Intestinally Restricted Drugs. *ACS Med Chem Lett*. 2023;14(3):233. doi:10.1021/ACSMEDCHEMLETT.3C00001
56. Hua S. Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological, Pathophysiological and Pharmaceutical Factors. *Front Pharmacol*. 2020;11:496058. doi:10.3389/FPHAR.2020.00524/FULL
57. Martin H, McGhie TK, Bentley-Hewitt K, Christeller J. PPAR α as a sensor of lipase activity and a target for the lipase inhibitor orlistat. *Lipids Health Dis*. 2013;12(1). doi:10.1186/1476-511X-12-48
58. Zhao Y, Zhang M, Hou X, et al. Design, synthesis and biological evaluation of salicylanilides as novel allosteric inhibitors of human pancreatic lipase. *Bioorg Med Chem*. 2023;91. doi:10.1016/J.BMC.2023.117413
59. Khan FI, Lan D, Durrani R, Huan W, Zhao Z, Wang Y. The lid domain in lipases: Structural and functional determinant of enzymatic properties. *Front Bioeng Biotechnol*. 2017;5(MAR):247303. doi:10.3389/FBIOE.2017.00016/FULL
60. Saeki K, Hayakawa S, Nakano S, et al. In Vitro and In Silico Studies of the Molecular Interactions of Epigallocatechin-3-O-gallate (EGCG) with Proteins That Explain the Health Benefits of Green Tea. *Mol* 2018, Vol 23, Page 1295. 2018;23(6):1295. doi:10.3390/MOLECULES23061295
61. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. *Nat Rev Mol Cell Biol*. 2012;13(4):251-262. doi:10.1038/NRM3311
62. Lanier M, Cole DC, Istratiy Y, et al. Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes. *J Med Chem*. 2017;60(12):5209-5215. doi:10.1021/ACS.JMEDCHEM.6B01224/SUPPL_FILE/JM6B01224_SI_003.CSV
63. Garner CW. Boronic acid inhibitors of porcine pancreatic lipase. *J Biol Chem*. 1980;255(11):5064-5068. doi:10.1016/s0021-9258(19)70749-2
64. Chang JW, Cognetta AB, Niphakis MJ, Cravatt BF. Proteome-wide reactivity profiling identifies diverse carbamate chemotypes tuned for serine hydrolase inhibition. *ACS Chem Biol*. 2013;8(7):1590-1599. doi:10.1021/CB400261H
65. Alexander JP, Cravatt BF. Mechanism of Carbamate Inactivation of FAAH: Implications for the Design of Covalent Inhibitors and In Vivo Functional Probes for Enzymes. *Chem Biol*. 2005;12(11):1179. doi:10.1016/J.CHEMBIOL.2005.08.011
66. Narayanan A, Jones LH. Sulfonyl fluorides as privileged warheads in chemical biology. *Chem Sci*. 2015;6(5):2650-2659. doi:10.1039/C5SC00408J
67. Rocha S, Proença C, Araújo AN, et al. Flavonoids as Potential Modulators of Pancreatic Lipase Catalytic Activity. *Pharmaceutics*. 2025;17(2):163. doi:10.3390/PHARMACEUTICS17020163/S1
68. Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. *J Clin Pharmacol*. 1995;35(11):1103-1108. doi:10.1002/J.1552-4604.1995.TB04034.X
69. Drug P, Information S, Food IUS. Orlistat (marketed as Alli and Xenical) Information. 2016;3500:1-2. Accessed November 18, 2025. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/orlistat-marketed-alli-and-xenical-information>
70. Hollingsworth SA, Dror RO. Molecular Dynamics Simulation for All. *Neuron*. 2018;99(6):1129-1143. doi:10.1016/J.NEURON.2018.08.011
71. Khan FI, Lan D, Durrani R, Huan W, Zhao Z, Wang Y. The lid domain in lipases: Structural and functional determinant of enzymatic properties. *Front Bioeng Biotechnol*. 2017;5(MAR):247303. doi:10.3389/FBIOE.2017.00016/FULL